Alexion Restructuring Deemed A Necessary Evil
Executive Summary
The painful cuts in the workforce and HQ relocation planned by the new executive team at Alexion may be necessary for the long-term health of the company.
You may also be interested in...
Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune
Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.
Alexion's Defensive Play Poised To Pay Off
The company's long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority to Soliris in a Phase III trial, which should help the company defend against anticipated competition to its blockbuster franchise.
Alexion Seizes On New Soliris Indication, Business Development For Growth
Alexion will target Soliris to about 3,000-8,000 US patients with ultra-rare generalized myasthenia gravis (gMG) following FDA approval. Meanwhile, the company has hired a new head of business development.